CEO turned informant: How the FDA built a case against executives promising cheap medications
The FDA's unprecedented criminal case against an alternative funding program hinged on the cooperation of a peer CEO, according to a court record.
Thursday, 19 November 2026
Independent coverage of global markets, trade and finance
Finance & markets
National Trade News capital-markets note (2026-11-18): The FDA's unprecedented criminal case against an alternative funding program hinged on the cooperation of a peer CEO, according to a court record. Primary source: original at CNBC Top News (cnbc.com).
CEO turned informant: How the FDA built a case against executives promising cheap medications
The FDA's unprecedented criminal case against an alternative funding program hinged on the cooperation of a peer CEO, according to a court record.